8-K: Teknova Reports Strong 2025 Growth, Targets 2027 Adjusted EBITDA Positive

Alpha Teknova, Inc. announced its fourth quarter and full year 2025 financial results, reporting increased revenue and improved profitability metrics, alongside 2026 revenue guidance.

Summary

• Full year 2025 total revenue was $40.5 million, representing a 7% increase year-over-year and aligning with guidance.
• Fourth quarter 2025 total revenue reached $10.0 million, an 8% increase over the same quarter in the prior year.
• The company provides 2026 revenue guidance of $42 million to $44 million.
• Adjusted EBITDA for the full year 2025 improved to negative $6.7 million, compared to negative $14.5 million in 2024.
• Free Cash Flow for the full year 2025 was negative $9.8 million, a significant improvement from negative $13.5 million in 2024 and better than the previously communicated target of less than negative $12 million.
• Teknova aims to become Adjusted EBITDA positive by the end of 2027.
• Anticipates full-year Free Cash Outflow of less than $10 million in 2026.
• Cash and short-term investments totaled $21.3 million, and gross debt was $13.2 million at the end of fiscal year 2025.
• Achieved 25% annual growth in the number of Clinical Solutions customers in 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report demonstrating significant operational improvements and a clear path towards profitability, despite continued net losses. The strong growth in Clinical Solutions and better-than-expected Free Cash Flow are encouraging.

Positives

• Full year 2025 total revenue of $40.5 million was up 7% year-over-year and in line with guidance.
• Fourth quarter 2025 total revenue of $10.0 million was up 8% over the same quarter prior year.
• Clinical Solutions revenue in Q4 2025 was $2.7 million, a 47% increase compared to $1.9 million in Q4 2024.
• Gross profit for Q4 2025 was $3.2 million, up from $2.1 million in Q4 2024, with gross margin improving to 32.5% from 23.0%.
• Full year 2025 gross profit was $13.4 million, significantly up from $7.2 million in 2024, with gross margin improving to 33.2% from 19.2%.
• Operating expenses for full year 2025 decreased to $30.4 million from $33.4 million in 2024, driven by reduced headcount and spending.
• Net loss for full year 2025 improved to $17.3 million, compared to $26.7 million in 2024.
• Adjusted EBITDA for full year 2025 improved to negative $6.7 million, compared to negative $14.5 million in 2024.
• Cash used in operating activities for full year 2025 decreased to $8.6 million from $12.4 million in 2024.
• Free Cash Flow for full year 2025 improved to negative $9.8 million, significantly better than the previously communicated target of less than negative $12 million.
• Achieved 25% annual growth in Clinical Solutions customers in 2025.
• Company targets becoming Adjusted EBITDA positive by the end of 2027.

Negatives

• The company continues to operate at a net loss of $17.3 million for the full year 2025.
• Adjusted EBITDA remains negative at $6.7 million for the full year 2025.
• Free Cash Flow remains negative at $9.8 million for the full year 2025.
• Total cash and short-term investments decreased from $30.396 million at December 31, 2024, to $21.338 million at December 31, 2025.

Risks

• The company's fourth quarter and year-end financial closing procedures, annual accounting procedures and adjustments, and annual audit of its financial statements are not yet complete.
• Demand for products, including the potential for delays or pausing of customer orders, could impact future revenue.
• The company's assessment of fundamental indicators of future demand across its target customer base may not be accurate.
• Uncertainties exist regarding cash flows and the revenue growth rate.
• Risks are present in the supply chain, sourcing, manufacturing, and warehousing operations.
• Challenges in inventory management could affect profitability.
• Global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East, could adversely affect operations.
• Potential acquisitions and the integration of other companies carry inherent risks.
• Other factors discussed in the Risk Factors section of the company's most recent periodic reports filed with the SEC, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, could impact results.

Future Outlook

Teknova anticipates total revenue of $42 million to $44 million for the fiscal year ending December 31, 2026. The company also expects Free Cash Outflow of less than $10 million for 2026 and aims to become Adjusted EBITDA positive by the end of 2027, driven by increased investment in commercial capabilities and an improving biotech funding environment.

Management Comments

• "After another successful year of disciplined execution against our strategic objectives, we've decided to further invest in our commercial capabilities this year." Stephen Gunstream, President and Chief Executive Officer.
• "As we begin to realize the benefits of the substantial capital investments we've made in recent years, and amid signs that the biotech funding environment is likely to continue to improve, we believe that additional and targeted commercial efforts should enable us to become Adjusted EBITDA positive by the end of 2027." Stephen Gunstream, President and Chief Executive Officer.
• "We delivered strong financial results in 2025 compared to 2024, including an acceleration of top line growth and continued significant improvement in Adjusted EBITDA and Free Cash Outflow." Matt Lowell, Chief Financial Officer.
• "Based on our revenue guidance of $42-44 million, and reflecting increased investment in our commercial capabilities, we anticipate full-year Free Cash Outflow of less than $10 million in 2026." Matt Lowell, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Teknova's increased investment in commercial capabilities and target of Adjusted EBITDA positive by 2027 aligns with a broader industry trend of biotech companies focusing on commercialization and profitability as the funding environment shows signs of improvement. The company's role as a critical reagent producer positions it to benefit from growth in novel therapies, vaccines, and molecular diagnostics.

Comparison to Industry Standards

• Teknova's 7% revenue growth in 2025 is modest compared to some high-growth biotech reagent suppliers, but the significant improvement in gross margin (from 19.2% to 33.2%) and reduction in net loss and Adjusted EBITDA deficit indicates strong operational efficiency gains, which is a positive sign in a competitive market.
• The target of Adjusted EBITDA positive by the end of 2027 suggests a longer path to profitability compared to more mature, established players in the life sciences tools sector, but the trajectory of improvement is notable.
• The 25% annual growth in Clinical Solutions customers is a strong indicator of market penetration in a key growth segment, potentially outpacing some competitors focused solely on research-use-only products.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company achieves its profitability targets and sustains revenue growth. Improved financial metrics and outlook could positively influence investor confidence.
• Employees: Continued investment in commercial capabilities may lead to new hiring in sales and marketing, while previous headcount reductions indicate ongoing efficiency efforts.
• Customers: Growth in Clinical Solutions customers and manufacturing efficiency gains suggest improved product offerings and service delivery.
• Creditors: Reduced Free Cash Outflow and improved financial health could enhance the company's creditworthiness.

Next Steps

• Further investment in commercial capabilities during 2026.
• Attend the TD Cowen 46th Annual Health Care Conference on March 4, 2026.
• Attend the KeyBanc Capital Markets Healthcare Forum on March 18, 2026.
• Attend the Sidoti Small Cap Conference on March 19, 2026.
• Attend the 38th Annual Roth Conference on March 23, 2026.
• Work towards becoming Adjusted EBITDA positive by the end of 2027.

Key Dates

Recommendation

Teknova demonstrated significant operational improvements in 2025, including better-than-expected Free Cash Flow and a clear path towards Adjusted EBITDA positivity by 2027. The growth in Clinical Solutions is a strong positive. However, the company remains unprofitable and cash flow negative, and the 2026 revenue guidance is modest. While the trajectory is positive, it's prudent for investors to hold and monitor execution against the 2027 profitability target and sustained revenue acceleration before considering a stronger position.

Keywords

Teknova, TKNO, financial results, biotech, life sciences, reagents, molecular diagnostics, therapies, vaccines, revenue, EBITDA, cash flow, guidance, clinical solutions, lab essentials, SEC filing, earnings